# An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

> **NCT02581631** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 145 (actual)

## Conditions studied

- Non-Hodgkin's Disease

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT02581631
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-11
- **Primary completion:** 2020-01-16
- **Final completion:** 2022-02-07
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2023-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581631, "An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02581631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*